# CorMedix Inc. (CRMD) — litigation/settled [announced]
Source: SEC API (secapi.ai) · situation sit_b33a020fe96a12babe02 · retrieved 2026-08-12T06:58:44.562Z

## Overview
CorMedix Inc. is a biopharmaceutical company primarily focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, including DefenCath (formerly Neutrolin).

CorMedix Inc. settled consolidated shareholder derivative litigation by agreeing to implement and maintain corporate governance reforms for a minimum of 3.5 years. The settlement resolves claims that individual defendants (officers and directors) breached fiduciary duties by making false or misleading statements regarding manufacturing deficiencies that delayed FDA approval of DefenCath. Plaintiffs' counsel intends to petition the court for attorneys' fees and expenses not to exceed $3,900,000. The settlement hearing is scheduled for September 23, 2026.

## Terms
- Counterparty: Plaintiffs (Melissa Voter, Isaac Desalvo, Rose Scullion, Amit Raval) and Individual Defendants (Khoso Baluch, Janet D. Dillione, Alan W. Dunton, Myron Kaplan, Steven Lefkowitz, Paulo F. Costa, Greg Duncan, Matthew David, Robert Cook, Joseph Todisco, Phoebe Mounts, John L. Armstrong) · Deal value: $3.9M

## Key dates
- Announced 2026-08-07 · Expected close 2026-09-23

## Timeline
- 2026-08-07 · 8-K (0001410098-26-000044): 8-K - CorMedix Inc. — *CorMedix Inc. is a biopharmaceutical company primarily focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, including DefenCath (formerly Neutrolin).* CorMedix Inc. settled consolidated shareholder derivative litigation by agreeing to implement and maintain corporate governance reforms for a minimum of 3.5 years. The settlement resolves claims that individual defendants (officers and directors) breached fiduciary duties by making false or misleading statements regarding manufacturing deficiencies that delayed FDA approval of DefenCath. Plaintiffs' counsel intends to petition the court for attorneys' fees and expenses not to exceed $3,900,000. The settlement hearing is scheduled for September 23, 2026.
  https://www.sec.gov/Archives/edgar/data/1410098/0001410098-26-000044.txt

## Citations
- 0001410098-26-000044 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000141009826000044